# Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

> **NCT00641030** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** clofarabine
- **DRUG:** melphalan
- **GENETIC:** gene expression analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00641030
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00641030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00641030, "Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00641030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*